Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, currently in a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.
Location: United States
Employees: 1-10
Total raised: $30.47M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Angel Phys... | angelphysi... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.12.2025 | Series B | $25M | Queen City... |
| 19.09.2022 | Series A | $3.3M | - |
| 20.05.2022 | - | $2.17M | - |
Mentions in press and media 7
| Date | Title | Description |
| 15.12.2025 | Alphyn Closes $25M Series B Financing | Alphyn Biologics, an Annapolis, MD-based clinical-stage dermatology company, raised $25M, in Series B funding. The round was led by QCA Investment Group and included existing investors Angel Physicians Fund, Serial Stage Venture Partners, a... |
| 12.12.2025 | Alphyn Biologics: $25 Million Series B Raised To Advance Dermatology Clinical Programs | Alphyn Biologics, a clinical-stage dermatology company focused on developing first-in-class multi-target therapeutics for severe and common skin diseases, has closed a $25 million Series B financing round, twice oversubscribed. QCA Investme... |
| 07.05.2025 | Skin in the Game: Meet May 19th Pitch Presenter Neal Koller of Alphyn Biologics | I met Neal, CEO of Alphyn Biologics, about four years ago when the company was very young. A few months ago, I got a call from Scott Jacobs at Queen City Angels suggesting we get in on a hot Series B round. The company? Alphyn Biologics. In... |
| 19.09.2022 | Alphyn Biologics Closes $3.3M Series A Financing | Alphyn Biologics, an Annapolis, Md.- and Cincinnati, Ohio-based clinical-stage dermatology company developing first-in-class multi-target therapeutics, closed a Series A financing round of approximately $3.3m. The round was led by Queen Cit... |
| - | Manage your consent preferences Queen City Angels leads Alphyn Biologics' $3.3M Series A | - |
| - | Alphyn Biologics | “Home - Alphyn” |
| - | Alphyn Biologics | “Alphyn Biologics is creating a new class of drugs, Multi-Target Therapeutics™, for more effective therapies to treat skin disease.” |